Our study pioneers multi-omics investigation (proteomics/metabolomics) to identify pLELC vulnerabilities, uncovering a novel LA/PPAR-α/TF axis that drives tumor progression—revealing actionable therapeutic targets. This evidence concerns the gene PPARA and neoplasm.